Sengenics flagship technology is the patented Immunome™ auto-antibody profiling platform which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge in 1996.The Immunome™ protein array can be used for understanding the role the immune system plays in cancer and autoimmune diseases. It can also be used to model human infections, response to drugs and external stresses.
